Takeda Pharmaceutical announced positive results from two phase III trials of oveporexton, an oral orexin receptor 2 (OX2R)-selective agonist for narcolepsy type 1. The drug met all primary and secondary endpoints, demonstrating statistically significant and clinically meaningful improvements in wakefulness, excessive daytime sleepiness, and muscle weakness symptoms. The safety profile was consistent with previous trials and well tolerated. Takeda plans to file regulatory approval applications within the fiscal year. This marks a key milestone, validating orexin receptor agonism as a viable treatment for narcolepsy and positioning the drug as a potential multibillion-dollar market entrant.